In one of the largest overseas acquisitions by an India pharmaceutical company, Ahmedabad-basedacquired the generics business of Actavis in the UK and Ireland from global generics giant Teva for an enterprise value of £600 million (Rs 5,100 crore) in an all-cash deal.
This is a big leap for the unlisted Indian company, which had annual revenue of Rs 6,569 crore, an earnings before interest, tax, depreciation and amortisation (Ebitda) margin of 22 per cent and net profit of Rs 882.5 crore in 2015-16.
sold these assets after the European Commission’s (EU) anti-trust divesture requirements arising from its acquisition of Actavis Generics.
The revenue of Teva’s UK and Ireland stood at £250 million (Rs 2,100 crore) in 2015.
Intas paid 2.4 times Teva UK’s revenue for the acquisition.
“This transaction represents a unique opportunity for Intas to build scale in the UK and in Ireland. It will add to our market-leading hospital franchise and create a strong platform for further European expansion,” said Binish Chudgar, vice-chairman and managing director of Intas.